The US Food and Drug Administration (USFDA) has revoked Voluntary Action Initiated (VAI) Status of Aurobindo Pharma’s Unit IV, a general injectable formulation manufacturing facility. The company has received a communication that the inspection conducted by the USFDA at its aforesaid Unit IV, from November 4,2019 to November 13, 2019, is still open and under review.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
